Search

Displaying results 1571 - 1580 of 5925 in total
  1. Drug

    Letrozole

    go.drugbank.com/drugs/DB01006
    ApprovedInvestigational

    Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990. It is a third generation aromatase inhibitor like exemestane and anastrozole, meaning it does not significantly affe...

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  2. Drug

    Amlexanox

    go.drugbank.com/drugs/DB01025
    ApprovedWithdrawn

    Amlexanox is an antiallergic drug, clinically effective for atopic diseases, especially allergic asthma and rhinitis. Amlexanox as a topical paste is a well tolerated treatment of recurrent aphthous ulcers. Recurrent aphthous ulcer (RAU)...

  3. Drug

    Flunisolide

    go.drugbank.com/drugs/DB00180
    Approved

    Flunisolide (marketed as AeroBid, Nasalide, Nasarel) is a corticosteroid with anti-inflammatory actions. It is often prescribed as treatment for allergic rhinitis and its principle mechanism of action involves activation of glucocorticoi...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inducers
  4. Drug

    Durlobactam

    go.drugbank.com/drugs/DB16704
    ApprovedInvestigational

    Durlobactam is a diazabicyclooctane non-beta-lactam, beta-lactamase inhibitor. It is typically given in combination with sulbactam to protect it from degradation by certain serine-beta-lactamases. The combination product of durlobactam a...

  5. Drug

    Equine Botulinum Neurotoxin F Immune FAB2

    go.drugbank.com/drugs/DB13901
    Approved

    Equine Botulinum Neurotoxin F Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype F. It is intravenously administered for the treat...

  6. Drug

    Finerenone

    go.drugbank.com/drugs/DB16165
    ApprovedInvestigational

    mineralocorticoid receptor antagonist indicated to reduce the risk of sustained decline in glomerular filtration rate, end stage kidney disease, cardiovascular death, heart attacks, and hospitalization due

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 Substrates
  7. Drug

    Fenofibrate

    go.drugbank.com/drugs/DB01039
    ApprovedInvestigational

    Fenofibrate is a fibric acid derivative like clofibrate and gemfibrozil. Fenofibrate is used to treat primary hypercholesterolemia, mixed dyslipidemia, severe hypertriglyceridemia. Fenofibrate was granted FDA approval on 31 December 1993.

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesSynonyms: Isopropyl (4'-(p-chlorobenzoyl)-2-phenoxy-2-methyl)propionate
  8. Drug

    Technetium Tc-99m pertechnetate

    go.drugbank.com/drugs/DB09314
    ApprovedInvestigational

    Technetium Tc-99m pertechnetate is a radiopharmaceutical diagnostic agent composed of an oxoanion with the chemical formula TcO4-. Pertechnetate has a wide variety of uses within nuclear medicine as it distributes within the body to a si...

    Mixtures: GENERADOR DE SOLUCION INYECTABLE DE PERTECNETATO (99MTC) DE SODIO. 2-50GBQ, TECHNELITE® GENERADOR DE TECNECIO TC 99M
  9. Drug

    Elsulfavirine

    go.drugbank.com/drugs/DB14929
    Investigational

    Elsulfavirine is under investigation in clinical trial NCT03706898 (Study to Evaluate the Safety and PK of Elpida® in Healthy Subjects and Patients With Hepatic Impairment and to Assess the Impact of Food

  10. Drug

    Tenocyclidine

    go.drugbank.com/drugs/DB01520
    IllicitInvestigational

    Tenocyclidine (TCP, thienyl cyclohexylpiperidine) is a dissociative anesthetic drug with stimulant and hallucinogenic effects. It is more potent than phencyclidine and hence, this drug was classified under the schedule 1 in 1970.